FORMULATION AND IN-VITRO EVALUATION OF CONTROLLED RELEASE MICROSPONGE GEL FOR TOPICAL DELIVERY OF CLOTRIMAZOLE
Markand Mehta
Department of Pharmaceutics, Sigma Institute of Pharmacy, Vadodara, Gujarat-390019, India.
Amish Panchal
Department of Pharmaceutics, Sigma Institute of Pharmacy, Vadodara, Gujarat-390019, India.
Viral H Shah
Department of Pharmaceutics, Sigma Institute of Pharmacy, Vadodara, Gujarat-390019, India.
Umesh Upadhyay
Department of Pharmaceutics, Sigma Institute of Pharmacy, Vadodara, Gujarat-390019, India.
Conventional drug delivery systems require periodic doses of the therapeutic agent to produce maximum therapeutic effect. For most drugs, conventional methods of drug administration are effective, except for some drugs which are unstable o r toxic, having narrow therapeutic window or some solubility problems. In the present study, Clotrimaz ole, BCS class II drug was used which having very less aqueous solubility, a shorter half-life (2.5-3 hr) and certain side effects like earythma, edema and skin irritation. So, encapsulation of Clotrimazole into microsponge would modified the release rate and also reduce side effects. In this study Clotrimazole microsponge was prepared by emulsion solvent diffusion technique by using Ethyl cellulose , HPMC K4M, Carbopol 934, Eudragit RS100, Eudragit S100, Eudragit RL100 and evaluated for % Practical yield, % Loading efficiency and In vitro drug release study. Drug- excipients compatibility was performed by FTIR study. Optimized batch of microsponge was further formulated as gel formulation for topical delivery. Prepared gel formulations were evaluated for physical parameters like viscosity, pH, clarity and In vitro drug permeation study. The drug release data of optimized batch were fitted into different kinetic models which show that the drug release from gel formulations follows zero order release. Optimized gel formulation was compared with the marketed formulation and pure drug for anti fungal activity, which shows that the prepared formulation is having comparative anti fungal activity with marketed formulation
2 , 2 , 2012
93 - 101